Global Organ-on-Chip Market 2025-2035

Organ-on-Chip Market Size, Share & Trends Analysis Report by Organ Type (Liver, Kidney, Intestine, Lung, Heart, and Other Organ), by Model Type (Organ-Based Model, and Disease-Based Model), by Product (Instrument, Consumables and Reagents, Software, and Service), by Application (Drug Discovery, Toxicology Research, Physiological Model, Tissue Regeneration & Regenerative Medicine, Stem Cell Research, and Others), and by End-User (Pharmaceutical & Biotechnology Industry, Academic & Research Institutes, and Cosmetics Industry), Forecast Period (2025-2035)

Industry Overview

Organ-on-a-chip market size was estimated at $130 million in 2024 and is projected to reach $4,035 million by 2035, growing at a CAGR of 36.7% from 2025 to 2035. The market growth is primarily driven by the increasing adoption of animal-free testing methods and the growing integration of organ-on-chip technology by pharmaceutical and biotechnology companies in drug development. Additionally, the increasing focus on drug discovery, the surge in organ failure cases, and the global rise in organ transplants are fueling advanced research and innovation in this field.

Market Dynamics

Increasing Demand for Animal-Free Testing and Government Support

Organ-on-chip technology has emerged as a promising alternative to traditional animal-based drug testing. A significant number of drug candidates fail in late-stage preclinical trials due to fundamental physiological and metabolic differences between animals and humans. This technology addresses such discrepancies by offering a more human-relevant testing model, enhancing the specificity and reliability of drug development. Furthermore, ethical concerns surrounding animal testing and the high attrition rate of drug candidates have accelerated the adoption of organ-on-chip systems. For instance, cosmetic testing on animals has been prohibited in Europe since 2013, reinforcing the global shift toward cruelty-free and more accurate testing methods.

Additionally, in December 2022, the US FDA passed the Modernization Act 2.0 to encourage the reduction of drug animal testing and reliance on alternative testing methods. Governments and private organizations are interested in the novel organ-on-chip technology. Many government organizations have collaborated with organ-on-chip companies to test the efficacy of organ-on-chip technology as a replacement for future drug discovery and development. For instance, CN Bio Innovation Ltd. (UK) worked with the US FDA to improve bioavailability estimation using multi-organ microphysiological systems.

Technological Development in Organ-on-Chip Systems

The advancement of organ-on-a-chip technologies such as microfluidics, 3D cell culture, bioprinting, and integration with AI enables precise cell and biomaterial deposition, real-time monitoring of cellular responses, and high-throughput drug screening and toxicity testing, thereby significantly driving market growth. This convergence addresses the limitations of traditional approaches (Such as animal testing, 2D cell cultures) and expedites the new drug development process.

Market Segmentation

• Based on the organ type, the market is segmented into liver, kidney, intestine, lung, heart, and other organs.
• Based on the model type, the market is segmented into organ-based models and disease-based models.
• Based on the product, the market is segmented into instruments, consumables and reagents, software, and service.
• Based on the application, the market is segmented into drug discovery, toxicology research, physiological model, tissue regeneration & regenerative medicine, stem cell research, and others.
• Based on the end-user, the market is segmented into the pharmaceutical & biotechnology industry, academic & research institutes, and the cosmetics industry.

Regional Outlook

The global organ-on-chip market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America is Projected to Dominate the Organ-on-chip Market

North America is projected to dominate the organ-on-chip market and is estimated to maintain its dominance with a significant CAGR during the forecast period. The factors propelling the growth of the organ-on-chip market in the region include rising investment by public and private sectors, increasing toxicological testing of chemicals on the different types of organ cells, and technological advancement and their rapid adoption. Moreover, the presence of leading market players and pharmaceutical companies such as Emulate, Inc., Nortis, Inc., AxoSim, and the Charles Stark Draper Laboratory in the U.S., along with OrganoBiotech in Canada, combined with strong government support and increasing awareness about organ-on-chip technology, is further accelerating market growth in the region. For instance, according to the Food and Drug Administration (FDA), the Modernization Act 2.0 aimed to clarify that the agency could use data from organ chips, computer models, cell-based assays, and other models to evaluate new drugs.

Market Players Outlook

The key players in the organ-on-chip market are contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market are Emulate, Inc., InSphero AG, MIMETAS B.V., SynVivo, Inc., and TissUse GmbH, among others. These market players adopt different marketing strategies such as mergers & acquisitions, R&D, product launches, partnership collaboration, and geographical expansions so on.

Recent Developments

• In April 2025, CN Bio entered into a strategic partnership with Pharmaron to advance the adoption of OoC technologies. Under this partnership, Pharmaron will validate CN Bio’s PhysioMimix platform for current applications and integrate OoC technologies into its R&D workflows. The partnership also includes joint efforts to explore new applications aimed at addressing unmet needs in drug discovery and development.
• In September 2024, Emulate, Inc., announced the release of its new Chip-R1 Rigid Chip, designed to minimize drug absorption and enhance biological modeling. Constructed using low-drug-absorbing plastics, Chip-R1 builds upon the core microfluidic design of Organ-Chips, offering researchers greater precision in predicting human drug responses.
• In June 2023, Emulate Inc. launched the Chip-A1 Accessible Chip as a part of an early access program. This innovation allows researchers to study complex tissue models in 3D, incorporating circulating immune cells or bacteria for enhanced biological relevance. Building upon the earlier Chip-S1, the Chip-A1 supports thicker tissue cultures and provides broader options for drug testing within epithelial culture environments.

The Report Covers

• Market value data analysis of 2024 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global organ-on-chip market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.

Show more